author-photo

Viviana Wilches

GlaxoSmithKline

3

Papers

9

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression: pOLAR month 12 results.

2021 AIDS
Show All
- Source
- Cite
- Save
Citations (0)
116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study

2020 Open Forum Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (1)